Advanced search
Publication Cover
Current Medical Research and Opinion Volume 27, 2011 - Issue 9
Submit an article Journal homepage
682
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension

Shunji YoshidaDivision of Rheumatology and Infectious Diseases, Department of Internal Medicine, Fujita Health University School of Medicine Aichi, JapanCorrespondence[email protected]
,
Kunio ShiratoDivision of Internal Medicine, Saito Hospital Ishinomaki, Japan
,
Ryutaro ShimamuraGlaxoSmithKline KK Tokyo, Japan
,
Norie NakaharaGlaxoSmithKline KK Tokyo, Japan
,
Takayuki IwaseGlaxoSmithKline KK Tokyo, Japan
&
Hiromu NakajimaGlaxoSmithKline KK Tokyo, Japan
Pages 1827-1834 | Accepted 12 Jul 2011, Published online: 04 Aug 2011

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Andrew J. Peacock, William Zamboni & Carmine Dario Vizza. (2015) Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review. Current Medical Research and Opinion 31:9, pages 1793-1807.
Read now
Shunji Yoshida, Kunio Shirato, Ryutaro Shimamura, Takayuki Iwase, Narumi Aoyagi & Hiromu Nakajima. (2012) Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension. Current Medical Research and Opinion 28:6, pages 1069-1076.
Read now

Articles from other publishers (10)

Qinhua Zhao, Na Guo, Jun Chen, Daniel Parks & Zhuang Tian. (2021) Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta‐analysis. Journal of Clinical Pharmacy and Therapeutics 47:2, pages 146-156.
Crossref
Kevin D. Hill, Anil R. Maharaj, Jennifer S. Li, Elizabeth Thompson, Piers C. A. Barker & Christoph P. Hornik. (2020) A Randomized, Controlled Pharmacokinetic and Pharmacodynamics Trial of Ambrisentan After Fontan Surgery. Pediatric Critical Care Medicine 21:9, pages e795-e803.
Crossref
Michael D. Aleo, Okechukwu Ukairo, Amanda Moore, Onyi Irrechukwu, David M. Potter & Richard P. Schneider. (2019) Liver safety evaluation of endothelin receptor antagonists using HepatoPac ® : A single model impact assessment on hepatocellular health, function and bile acid disposition . Journal of Applied Toxicology 39:8, pages 1192-1207.
Crossref
Masaharu Kataoka, Toru Satoh, Hiromi Matsubara, Koji Yamamoto, Tsukasa Inada, Kazunari UmezawaTomohiko TakahashiAtsushi NakanoKeiichi Fukuda. (2019) Safety and Efficacy of Ambrisentan–Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice. Circulation Reports 1:6, pages 268-275.
Crossref
Tomohiko Takahashi, Satoru Hayata, Akihiro Kobayashi, Yuna Onaka, Takeshi Ebihara & Terufumi Hara. (2017) Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim Analysis Report). Clinical Drug Investigation 38:3, pages 219-229.
Crossref
Y. Huo, Z. C. Jing, X. F. Zeng, J. M. Liu, Z. X. Yu, G. C. Zhang, Y. Li, Y. Wang, Q. S. Ji, P. Zhu, B. X. Wu, Y. Zheng, P. P. Wang & J. Li. (2016) Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study. BMC Cardiovascular Disorders 16:1.
Crossref
Kishan S. Parikh, Sudarshan Rajagopal, Kristine Arges, Tariq Ahmad, Joseph Sivak, Prashant Kaul, Svati H. Shah, Victor Tapson, Eric J. Velazquez, Pamela S. Douglas & Zainab Samad. (2015) Use of outcome measures in pulmonary hypertension clinical trials. American Heart Journal 170:3, pages 419-429.e3.
Crossref
Jamie J. Coleman & Anthony R. Cox. 2014. A worldwide yearly survey of new data in adverse drug reactions and interactions. A worldwide yearly survey of new data in adverse drug reactions and interactions 363 385 .
Michele D’Alto. (2012) An update on the use of ambrisentan in pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease 6:6, pages 331-343.
Crossref
. (2012) Current World Literature. Current Opinion in Nephrology & Hypertension 21:5, pages 557-566.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.